Derived from Current Agreements, the partnering scorecard gives an instant overview of the top partnering deals in the life sciences by year since 2010.
The following article contains a snapshot of the largest deals by value for the year.
Our Current Agreements database stores and categorizes deal data dating as far back as 2000 saving you valuable time on your deal making research activities.
|Searching for more deal information? Current Partnering offers the following options: |
Top partnering deals of 2020 valued at over US$500m.
|Abbvie, Genmab||Jun 2020||3800||Collaboration, co-development, licensing and co-promotion agreement for bispecific antibody products, including epcoritamab|
AbbVie and Genmab have signed a broad collaboration agreement to jointly develop and commercialize three of Genmab's early-stage investigational bispecific antibody product candidates and enter into a discovery research collaboration for future differentiated antibody therapeutics for cancer.
The companies will partner to develop Genmab's next-generation bispecific antibody programs, epcoritamab (DuoBody-CD3xCD20), DuoHexaBody-CD37 and DuoBody-CD3x5T4.
The collaboration combines Genmab's world-class discovery and development engine and next-generation bispecific antibody therapeutic candidates with AbbVie's deep clinical expertise, innovative antibody-drug conjugate (ADC) platform and global commercial leadership in hematological cancers.
The discovery research collaboration will combine proprietary antibodies from both companies along with Genmab's DuoBody technology and AbbVie's payload and ADC technology to select and develop up to four additional differentiated next-generation antibody-based product candidates, potentially across both solid tumors and hematological malignancies.
Genmab's DuoBody-CD3 technology engages and directs cytotoxic T cells selectively to tumors to elicit an immune response towards malignant tumor cells.
AbbVie's ADC technology allows the delivery of a therapeutic toxin directly to cancer cells while sparing normal, healthy cells, providing for a more targeted, less toxic treatment approach.
This collaboration will provide for the joint development and commercialization of the three bispecific antibody therapeutic candidates.
For epcoritamab, the companies will share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization.
Genmab will book net sales in the U.S. and Japan and receive tiered royalties on remaining global sales.
For DuoHexaBody-CD37, DuoBody-CD3x5T4 and any product candidates developed as a result of the companies' discovery research collaboration, Genmab and AbbVie will share responsibilities for global development and commercialization in the U.S. and Japan.
Genmab retains the right to co-commercialize these products, along with AbbVie, outside of the U.S. and Japan.
For the discovery research partnership, Genmab will conduct Phase 1 studies for these programs.
AbbVie retains the right to opt-in to program development.
AbbVie will pay Genmab USD 750 million in upfront payment with the potential for Genmab to receive up to USD 3.15 billion in additional development, regulatory and sales milestone payments for all programs as well as tiered royalties between 22% and 26% on net sales for epcoritamab outside the U.S. and Japan.
Except for these royalty-bearing sales, the parties share in pre-tax profits from the sale of products on a 50:50 basis.
Included in these potential milestones are up to USD 1.15 billion in payments related to clinical development and commercial success across the three existing bispecific antibody programs.
In addition, if all four next-generation antibody product candidates developed as a result of the discovery research collaboration are successful, Genmab is eligible to receive up to USD 2.0 billion in option exercise and success-based milestone payments.
|Fate Therapeutics, Janssen Biotech||Apr 2020||3100||Collaboration, option, licensing and co-promotion agreement for iPSC-derived cell-based cancer immunotherapies|
Fate Therapeutics announced a global collaboration and option agreement with Janssen Biotech.
Janssen will contribute proprietary antigen binding domains for up to four tumor-associated antigen targets.
The Company will apply its iPSC product platform to research and preclinically develop new iPSC-derived chimeric antigen receptor (CAR) NK and CAR T-cell product candidates.
The Company will receive $50 million in cash and $50 million from the purchase by Johnson & Johnson Innovation of newly issued shares of the Company’s common stock at a price per share of $31.00.
Janssen will also reimburse the Company for all activities conducted under the collaboration.
The Company will advance candidates under the collaboration to the filing of an Investigational New Drug (IND) application, after which Janssen will have the right to exercise its option for an exclusive license for the development and commercialization of collaboration candidates targeting the tumor-associated antigens.
The Company will be primarily responsible for the manufacture of collaboration candidates, the cost of which will be paid for by Janssen.
The Company is eligible to receive payments of up to $1.8 billion upon the achievement of development and regulatory milestones and up to $1.2 billion upon the achievement of commercial milestones, plus double-digit royalties on worldwide commercial sales of products targeting the antigens.
In addition, the Company has the right to elect to co-commercialize each collaboration candidate in the U.S. and share equally in profits and losses in the U.S., subject to its payment of certain clinical development costs and adjustments in milestone and royalty payments.
|Bristol-Myers Squibb, Repare Therapeutics||May 2020||3065||Collaboration agreement for SNIPRx synthetic lethal discovery platform to identify multiple oncology drug candidates|
Repare Therapeutics has entered into an exclusive, worldwide research collaboration with Bristol Myers Squibb.
Under the terms of the agreement, the companies will leverage Repare’s proprietary, CRISPR-enabled genome-wide synthetic lethal target discovery platform, SNIPRx, to jointly identify multiple synthetic lethal precision oncology targets for drug candidates.
Repare will grant BMS exclusive worldwide rights to develop and commercialize therapeutics for select validated synthetic lethal precision oncology targets discovered under the collaboration.
BMS will make an upfront payment of $65 million which includes a $15 million equity investment in Repare.
Repare will be eligible to receive up to approximately $3 billion in license fees, discovery, development, regulatory and sales-based milestones, in addition to royalty payments on net sales of each product commercialized by BMS.
|WuXi Biologics||Feb 2020||3000||Manufacturing agreement for vaccine products|
WuXi Biologics announced that WuXi Vaccines has entered into a strategic partnership with a global vaccine leader and signed a 20-year vaccine manufacturing contract valued approximately $3 billion USD, pursuant to which WuXi Vaccines will build a dedicated facility and supply a commercial vaccine products for the global market.
WuXi Vaccines will build an integrated vaccine manufacturing facility including drug substance manufacturing (DS), drug product manufacturing (DP), Manufacture Science and Technology Labs (MS&T) as well as Quality Control labs (QC).
The facility will be dedicated to manufacture one of its partner's vaccine products for the global market.
The new facility is expected to be operational in 2022.
|Biogen, Sangamo BioSciences||Feb 2020||2720||Collaboration and licensing agreement for gene regulation therapies for Alzheimer’s, Parkinson’s, neuromuscular, and other neurological diseases|
Biogen and Sangamo Therapeutics have executed a global licensing collaboration agreement to develop and commercialize ST-501 for tauopathies including Alzheimer’s disease, ST-502 for synucleinopathies including Parkinson’s disease, a third undisclosed neuromuscular disease target, and up to nine additional undisclosed neurological disease targets.
The companies will leverage Sangamo’s proprietary zinc finger protein (ZFP) technology delivered via adeno-associated virus (AAV) to modulate the expression of key genes involved in neurological diseases.
Biogen has exclusive global rights to ST-501 for tauopathies including Alzheimer’s disease, ST-502 for synucleinopathies including Parkinson’s disease, and a third undisclosed neuromuscular disease target.
In addition, Biogen has exclusive rights to nominate up to nine additional undisclosed targets over a target selection period of five years.
Sangamo will perform early research activities, costs for which will be shared by the companies, aimed at the development of the combination of proprietary CNS delivery vectors and ZFP-TFs targeting therapeutically relevant genes.
Biogen will then assume responsibility and costs for the investigational new drug-enabling studies, clinical development, related regulatory interactions, and global commercialization.
Sangamo will be responsible for GMP manufacturing activities for the initial clinical trials for the first three products of the collaboration and plans to leverage its in-house manufacturing capacity.
Biogen will assume responsibility for GMP manufacturing activities beyond the first clinical trial for each of the first three products.
Sangamo will receive $350 million comprised of $125 million in a license fee payment and $225 million from the sale of new Sangamo stock, or approximately 24 million shares at $9.21 per share.
Sangamo may receive up to $2.37 billion in other development, regulatory, and commercial milestone payments, including up to $925 million in pre-approval milestone payments and up to $1,445 million in first commercial sale and other sales-based milestone payments.
Sangamo will also be eligible to receive from Biogen tiered high single digit to sub-teen double-digit royalties on potential net commercial sales of products arising from the collaboration.
|Nurix, Sanofi||Jan 2020||2555||Collaboration, option, co-development and co-promotion agreement for targeted protein degradation therapies|
Nurix Therapeutics announced a global strategic collaboration with Sanofi to discover, develop and commercialize a pipeline of innovative targeted protein degradation drugs for patients with challenging diseases in multiple therapeutic areas.
Nurix will utilize its proprietary drug discovery platform, DELigase, that integrates its DNA-encoded libraries (DEL) and its unparalleled portfolio of E3 ligases to create small molecules designed to induce degradation of three specified drug targets, with an option by Sanofi to expand to a total of five targets.
Sanofi will have exclusive rights and be responsible for clinical development and commercialization of drug candidates resulting from the work while Nurix will retain the option to co-develop and co-promote up to two products in the United States under certain conditions.
The collaboration excludes Nurix’s lead degradation programs for which Nurix retains all rights.
Nurix will receive an upfront payment of $55 million and subsequent payments upon expansion of the number of targets to be included in the collaboration.
In addition, Nurix will be eligible to receive up to approximately $2.5 billion in total payments based on the successful completion of certain research, pre-clinical, clinical, regulatory and sales milestones.
For those programs that Nurix exercises its option to co-develop and co-promote, the parties will split U.S. profits and losses evenly and Nurix will be eligible to receive royalties on ex-U.S. net sales on all optioned products.
|Astex Pharmaceuticals, Merck and Co, Taiho||Jan 2020||2550||Collaboration, licensing, option and co-promotion agreement for small molecule inhibitors against several drug targets including KRAS oncogene|
Merck announced an exclusive worldwide research collaboration and license agreement with Taiho Pharmaceutical and Astex Pharmaceuticals focused on the development of small molecule inhibitors against several drug targets, including the KRAS oncogene, which are currently being investigated for the treatment of cancer.
Merck, Taiho and Astex will combine preclinical candidates and their data with knowledge and expertise from their respective research programs.
In exchange for providing Merck an exclusive global license to their small molecule inhibitor candidates, Taiho and Astex will receive an aggregate upfront payment of $50 million and will be eligible to receive approximately $2.5 billion contingent upon the achievement of preclinical, clinical, regulatory and sales milestones for multiple products arising from the agreement, as well as tiered royalties on sales.
Merck will fund research and development and will be responsible for commercialization of products globally.
Taiho has retained co-commercialization rights in Japan and an option to promote in specific areas of South East Asia.
|Innovent Biologics, Roche||Jun 2020||2100||Collaboration agreement for multiple products including cellular therapies and bispecific antibodies|
Innovent Biologics announced a strategic research and development collaboration with Roche covering multiple cell therapies and bispecific antibodies.
The collaboration will focus on the discovery, clinical development and commercialization of bispecific antibodies and multiple cell therapies and will be directed to the treatment of hematological and solid cancers.
Innovent will pay upfront, development and commercial milestone payments, and royalties, to non-exclusively access certain Roche technologies that enable the discovery and development of specific 2:1 T-cell bispecific antibodies (TCB) and the universal CAR-T platform.
Innovent will create, develop, manufacture, and commercialize the products. Roche retains an option right to license each product for ex-China development and commercialization.
Should Roche exercise all of its options, it will pay option exercise payments totaling $140 million plus additional development, approval, and sales milestone payments up to $1.96 billion if all products are successfully developed and commercialized.
Roche will pay double-digit up to mid teen percentage royalties on each product.
|Neurocrine Biosciences, Takeda Pharmaceutical||Jun 2020||2015||Collaboration and licensing agreement for therapies for psychiatric disorders|
Neurocrine Biosciences and Takeda Pharmaceutical announced a strategic collaboration to develop and commercialize compounds in Takeda’s early-to-mid-stage psychiatry pipeline.
Specifically, Takeda granted an exclusive license to Neurocrine Biosciences for seven pipeline programs, including three clinical stage assets for schizophrenia, treatment-resistant depression and anhedonia.
Neurocrine Biosciences will be responsible for developing and commercializing all pipeline compounds included in the collaboration.
Takeda will receive a total of $120 million USD in upfront cash.
Takeda will be entitled to development milestones of up to $495 million USD, commercial milestones of up to $1.4 billion USD and up to double-digit royalties on net sales.
At certain development events, Takeda may elect to opt in or out of a 50:50 profit share on all clinical programs on an asset-by-asset basis.
For any asset in which Takeda is participating in a 50:50 profit share arrangement, Takeda will not be eligible to receive development or commercial milestones.
|Incyte, MorphoSys||Jan 2020||2000||Collaboration, licensing and co-promotion agreement for Tafasitamab|
MorphoSys and Incyte have entered into a collaboration and license agreement to further develop and commercialize MorphoSys' proprietary anti-CD19 antibody tafasitamab (MOR208) globally.
Tafasitamab is an Fc-engineered antibody against CD19 currently in clinical development for the treatment of B cell malignancies.
MorphoSys and Incyte will co-commercialize tafasitamab in the U.S., while Incyte has exclusive commercialization rights outside of the U.S.
MorphoSys will receive an upfront payment of $750 million and, in addition, Incyte will make an equity investment into MorphoSys of $150 million in new American Depositary Shares (ADS) of MorphoSys at a premium to the share price at signing of the agreement.
Depending on the achievement of certain developmental, regulatory and commercial milestones, MorphoSys will be eligible to receive milestone payments amounting to up to $1.1 billion.
MorphoSys will also receive tiered royalties on ex-U.S. net sales of tafasitamab in a mid-teens to mid-twenties percentage range of net sales.
In the U.S., MorphoSys and Incyte will co-commercialize tafasitamab, with MorphoSys leading the commercialization strategy and booking all revenues from sales of tafasitamab.
Incyte and MorphoSys will be jointly responsible for commercialization activities in the U.S. and will share profits and losses on a 50:50 basis.
Outside the U.S., Incyte will have exclusive commercialization rights, and will lead the commercialization strategy and book all revenues from sales of tafasitamab, paying MorphoSys royalties on ex-U.S. net sales.
Furthermore, the companies will share development costs associated with global and U.S.-specific trials at a rate of 55% (Incyte) to 45% (MorphoSys); Incyte will cover 100% of the future development costs for trials that are specific to ex-U.S. countries.
Both parties have agreed to co-develop tafasitamab broadly in relapsed/refractory diffuse large B cell lymphoma (r/r DLBCL), frontline DLBCL as well as additional indications beyond DLBCL, such as follicular lymphoma (FL), marginal zone lymphoma (MZL) and chronic lymphocytic leukemia (CLL).
Incyte will be responsible for initiating a combination study of its investigational PI3K-delta inhibitor parsaclisib and tafasitamab in r/r B cell malignancies.
Further, Incyte will be responsible for leading any potential registration-enabling studies in CLL and a phase 3 trial in r/r FL/MZL. MorphoSys will continue to be responsible for its currently ongoing clinical trials of tafasitamab in non-Hodgkin lymphoma (NHL), CLL, r/r DLBCL and frontline DLBCL. The parties will share responsibility in starting additional global trials, and Incyte intends to pursue development in additional territories including Japan and China.
MorphoSys recently submitted a Biologics License Application (BLA) for tafasitamab, in combination with lenalidomide, to the U.S. Food and Drug Administration (FDA) for the treatment of r/r DLBCL; the FDA decision regarding a potential approval is expected by mid-2020.
The submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in r/r DLBCL is planned for mid-2020.
|Alnylam Pharmaceuticals, Blackstone Medical||Apr 2020||2000||Royalty financing agreement to facilitate RNAi therapeutics|
Blackstone Medical and Alnylam Pharmaceuticals have entered into a broad strategic collaboration under which Blackstone will provide up to $2 billion to support Alnylam’s advancement of innovative RNA interference (RNAi) medicines that have the potential to transform the lives of patients suffering from a range of debilitating diseases.
The deal is anchored by Blackstone’s purchase of 50 percent of the royalties owed to Alnylam on global sales of inclisiran, an investigational RNAi therapeutic for the treatment of hypercholesterolemia, currently under review by the U.S. Food and Drug Administration.
Inclisiran is a twice-a-year, subcutaneously injected RNAi therapeutic that has been shown in a comprehensive Phase 3 program to reduce low-density lipoprotein (LDL) or “bad” cholesterol with an acceptable safety profile.
If approved, this medicine is expected to help patients lower LDL cholesterol, a major risk factor for cardiovascular disease, the leading cause of mortality in the U.S. and globally.
The strategic financing collaboration, led by Blackstone Life Sciences and GSO Capital Partners, Blackstone’s credit platform, is expected to enable Alnylam’s achievement of a self-sustainable financial profile without need for future equity financing, accelerating the commercial potential of Alnylam’s rapidly advancing product portfolio.
The investment by multiple Blackstone businesses will support the development and delivery of promising medicines to the patients who need them and is one of the largest ever private financings of a biotech company.
The transaction includes the inclisiran royalty monetization, corporate debt, purchase of Alnylam equity, and funding for certain R&D activities related to the clinical advancement of two Alnylam investigational RNAi therapeutic programs in cardiovascular disease.
Specifically, the transaction is comprised of the following components:
$1 billion in committed payments, led by Blackstone Life Sciences, to acquire 50 percent of Alnylam’s royalties and commercial milestones for inclisiran;
Up to $750 million in a first lien senior secured term loan led by GSO;
Up to $150 million from Blackstone Life Sciences for development of Alnylam’s cardiometabolic programs vutrisiran and ALN-AGT (to be established based upon a non-binding letter of intent);
$100 million purchase of Alnylam common stock.
|Arcus Biosciences, Gilead Sciences||May 2020||1900||Co-development and co-promotion agreement for next-generation cancer immunotherapies|
Gilead Sciences and Arcus Biosciences have entered into a 10-year partnership to co-develop and co-commercialize current and future therapeutic product candidates in Arcus’s pipeline.
The agreement will also provide ongoing funding to support Arcus’s research and development programs.
Arcus will receive $375 million upon closing, consisting of a $175 million upfront payment and a $200 million equity investment from Gilead.
Arcus is eligible to receive up to $1.225 billion in opt-in and milestone payments with respect to its current clinical product candidates.
Gilead will gain access to Arcus’s current and future investigational immuno-oncology products through the agreement, as Gilead continues to expand its presence in the field.
This includes immediate rights to zimberelimab, as well as the right to opt-in to all other current Arcus clinical candidates, which include AB154, AB928 and AB680, upon payment of an opt-in fee that ranges from $200 million to $275 million per program, after delivery of a qualifying data package.
If Gilead opts-in to the AB154 program, Arcus is eligible to receive up to $500 million in potential future U.S. regulatory approval milestones.
Gilead will receive the right to opt-in to all other programs that emerge from Arcus’s research portfolio over the next 10 years, upon payment of an opt-in fee of $150 million per program after Arcus’s delivery of a qualifying data package.
Upon Gilead’s exercise of its option for a program, unless Arcus opts out according to terms of the agreement, the companies will co-develop and share global development costs and will co-commercialize and share profits in the United States.
Gilead will obtain exclusive rights to commercialize any optioned programs outside of the U.S., subject to any rights of Arcus’s existing partners, and for which Gilead will pay to Arcus tiered royalties ranging from high-teens to low twenties.
Gilead will further provide ongoing research and development support of up to $400 million over the collaboration term.
Gilead will have the right to appoint two individuals to Arcus’s Board of Directors upon closing of the transaction.
Gilead’s $200 million equity investment will be at a price per share of $33.54. Additionally, Gilead will have the right to purchase additional shares from Arcus, up to a maximum of 35% of the outstanding voting stock of Arcus over the course of the next five years, at a 20% premium at the time Gilead exercises such option, or, if greater, at the initial purchase price per share.
|Bicycle Therapeutics, Genentech||Feb 2020||1730||Collaboration and licensing agreement for Bicycle-based immuno-oncology therapies|
Bicycle Therapeutics has entered into a strategic collaboration agreement with Genentech to discover, develop and commercialize novel Bicycle-based immuno-oncology therapies.
By entering into this early discovery collaboration with Genentech, Bicycle will be exploring its technology on a wider range of immuno-oncology targets, combining the expertise of both companies.
Bicycle brings its proprietary discovery platform, which allows rapid screening of novel targets to identify Bicycles and the ability to readily conjugate these together to create novel molecules that may overcome the potential limitations of other modalities.
Genentech brings to the collaboration its knowledge of immuno-oncology drug discovery and emerging target biology, as well as its development and commercialization expertise.
Genentech and Bicycle will collaborate on the discovery and pre-clinical development of novel Bicycle-based immunotherapies against multiple targets.
Bicycle will be responsible for discovery research and early pre-clinical development up to candidate selection, and Genentech will be responsible for further development and commercialization upon the selection of candidates.
None of Bicycle’s wholly owned oncology pipeline, including its immuno-oncology candidates, are included in the collaboration.
Bicycle will receive a $30 million upfront payment.
The upfront payment and potential discovery, development, regulatory and commercial-based milestone payments could total up to $1.7 billion.
Bicycle will also be eligible to receive tiered royalties on Bicycle-based medicines commercialized by Genentech.
|Astellas Pharma, CytomX Therapeutics||Mar 2020||1680||Collaboration, licensing, option and co-promotion agreement for Probody T-cell engaging bispecific therapies for cancer|
CytomX Therapeutics and Astellas Pharma have entered into a strategic collaboration agreement focused on the discovery, research, development and commercialization of novel T-cell engaging bispecific antibodies targeting CD3 and tumor cell surface antigens for the treatment of cancer.
The parties will utilize CytomX’s Probody therapeutic technology platform, as well as its proprietary bispecific formats and CD3 modules.
CytomX and Astellas will collaborate on several initial programs.
CytomX will lead research and discovery activities, up to clinical candidate selection, that will be funded by Astellas.
Astellas will lead and fund preclinical and clinical development and commercialization activities.
Astellas will make an upfront cash payment of $80 million to CytomX with CytomX eligible to receive future preclinical, clinical and commercial milestones of over $1.6 billion.
CytomX is also eligible to receive tiered royalties on global net sales that range from high-single digits to mid-teens.
For a specified number of targets, prior to the initiation of the first pivotal clinical trial for a product directed toward such target, CytomX may exercise an option to co-fund a pre-determined portion of clinical development costs.
For these products, CytomX is eligible to receive a pre-specified portion of profits in the United States and tiered low-double digit to mid-teen percentage royalties on net sales outside of the United States.
CytomX may later elect to co-commercialize the products directed toward such targets in the United States.
|Affinia Therapeutics, Vertex Pharmaceuticals||Apr 2020||1600||Collaboration, option and licensing agreement for AAV capsids for genetic therapies|
Vertex Pharmaceuticals and Affinia Therapeutics have entered into a strategic research collaboration to engineer novel adeno-associated virus (AAV) capsids to deliver transformative genetic therapies to people with serious diseases.
Affinia Therapeutics’ proprietary AAVSmartLibrary and associated technology provides capsids for improved tissue tropism, manufacturability and pre-existing immunity.
The collaboration will leverage Affinia Therapeutics’ capsid engineering expertise and Vertex’s scientific, clinical and regulatory capabilities to accelerate the development of genetic therapies for people affected by Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and cystic fibrosis (CF).
Affinia Therapeutics will apply its vector design and engineering technologies to develop novel capsids with improved properties.
The agreement provides Vertex an exclusive license under Affinia Therapeutics’ proprietary technology and intellectual property (IP) in DMD and DM1 with an exclusive option to license rights for CF and an additional undisclosed disease.
The scope of the agreement covers all genetic therapy modalities in these diseases.
Affinia Therapeutics will be eligible to receive over $1.6 billion in upfront and development, regulatory and commercial milestones, including $80 million in upfront payments and research milestones that will be paid during the research term, plus tiered royalties on future net global sales on any products that result from the collaboration.
Affinia Therapeutics will be responsible for the discovery of capsids that meet certain pre-determined criteria.
Vertex will be responsible for and will fund the design and manufacturing of genetic therapies incorporating the selected capsids, preclinical and clinical development efforts, and commercialization of any approved products in the licensed diseases.
|Amunix, Hoffmann La Roche, Roche||Jan 2020||1540||Licensing agreement for technology platform, XTEN, to discover and develop non-oncology therapeutics|
Amunix Pharmaceuticals has provided a technology license to F. Hoffmann-La Roche and Hoffmann-La Roche to utilize Amunix’s technology platform, XTEN, to discover and develop non-oncology therapeutics against certain undisclosed targets.
This agreement builds on Amunix’s previous technology assessment with Roche focused on using XTEN, a proprietary unstructured polypeptide, to extend drug half-life.
Amunix will receive a $40 million upfront payment from Roche.
Amunix may also receive up to $1.5 billion in payments from Roche associated with the achievement of certain developmental and sales milestones, plus royalties on sales of commercialized products.
|Gilead Sciences, Second Genome||Apr 2020||1538||Collaboration, option and licensing agreement for biomarker and inflammatory bowel disease drug discovery|
Gilead Sciences and Second Genome have entered into a four-year strategic collaboration to identify biomarkers associated with clinical response in up to five of Gilead’s pipeline compounds in inflammation, fibrosis and other diseases, and to identify potential new targets and drug candidates for the treatment of inflammatory bowel disease (IBD).
Second Genome will utilize its proprietary Microbiome Analytics Platform to identify novel biomarkers associated with clinical response to Gilead’s investigational medicines.
This work will harness the latest insights in microbiome science to help inform patient stratification and optimize potential treatments for patients in the future.
The platform, in combination with additional discovery and development tools, will also seek to identify new targets and drug candidates relevant to IBD.
This will include the identification of up to five novel IBD targets or drug candidates over the next four years, with an option to extend the collaboration for an additional two years.
Second Genome will receive $38 million in an upfront payment, and up to approximately $300 million in success-based preclinical, clinical, regulatory and commercial milestones for each of five target discovery programs as well as low double-digit royalties for any approved products.
In addition, it will receive success-based milestones for each validated biomarker delivered under the agreement.
Gilead will have the option to worldwide rights for up to five programs for all diseases as well as exclusive rights to all biomarkers developed under the collaboration.
|Aro Biotherapeutics, Ionis Pharmaceuticals||Jan 2020||1400||Collaboration and licensing agreement for cell-specific delivery of antisense oligonucleotides|
Aro Biotherapeutics has entered a licensing and collaboration agreement with Ionis Pharmaceuticals through which Ionis will use Aro’s CENTYRIN technology to develop targeted cell- and tissue- specific delivery of antisense oligonucleotides (ASOs).
Under the terms of the agreement, the companies will collaborate to create unique ASO-Centyrin conjugates that are designed to achieve tissue specific, therapeutically effective gene knockdown in extra-hepatic tissues with systemic administration.
Under the terms of the agreement, the two companies have agreed to jointly work towards advancing a defined number of ASO-Centyrin drug conjugates.
Aro will be responsible for Centyrin discovery and will collaborate with Ionis to create lead ASO-Centyrin drug conjugates for further development.
Ionis will be responsible for development and will have global commercialization rights for each ASO-Centyrin drug conjugate.
The parties will also collaborate on additional discovery programs.
Aro will receive an upfront cash payment, funding to support R&D efforts, and payments associated with the achievement of specific development and commercial milestones, up to $1.4B.
In addition, Aro will receive royalties on net sales.
|Eli Lilly, Evox Therapeutics||Jun 2020||1220||Collaboration and licensing agreement for DeliverEX platform for RNA interference and antisense oligonucleotide drug payloads for neurological disorders|
Evox Therapeutics announced a research collaboration and license agreement with Eli Lilly to leverage Evox's proprietary DeliverEX platform to develop and deliver RNA interference (RNAi) & antisense oligonucleotide (ASO) drug payloads for the potential treatment of neurological disorders.
During this research collaboration and five-target license agreement, Evox will be responsible for exosome engineering in order to achieve brain/CNS-targeting, drug loading and analytics and some in vitro assay development, as well as material supply for initial in vivo studies.
Any resulting candidate handover and technology transfer to Lilly will occur after pre-clinical proof of concept studies have been completed.
Evox will receive a $20 million cash up-front payment, research funding over three years, as well as a $10 million investment from Lilly in exchange for a convertible bond from the Company.
Evox will also be eligible for potential pre-clinical and clinical development, regulatory and commercial milestones of up to approximately $1.2 billion, as well as tiered royalties up to low double digits on net sales of products arising from the collaboration.
|Accent Therapeutics, AstraZeneca||Jun 2020||1155||Collaboration, option and licensing agreement for therapeutics targeting RNA-modifying proteins (RMPs) for treatment of cancer|
Accent Therapeutics and AstraZeneca will collaborate to discover, develop and commercialize transformative therapeutics targeting RNA-modifying proteins (RMPs) for the treatment of cancer.
The collaboration combines Accent’s expertise as a leader in the biology, target identification and drug discovery of RMP-targeting therapies with AstraZeneca’s industry leading expertise in oncology.
Accent will be responsible for research and development activities for a nominated preclinical program through to the end of Phase I clinical trials.
Following completion of Phase I, AstraZeneca will lead development and commercialization activities for the nominated program, with Accent having the option to jointly develop and commercialize with AstraZeneca in the US.
AstraZeneca will also have the exclusive option to license worldwide rights to two further preclinical discovery programs, for which Accent will conduct certain preclinical activities.
Accent will receive an upfront payment of $55 million and, in the event that Accent elects to jointly develop the nominated program, is eligible to receive up to $1.1 billion in additional success-based payments across all programs in the form of option fees and milestone payments, as well as tiered royalties on net sales ranging from mid-single digit to low-double digits.
In the event Accent opts into co-developing and co-commercializing the nominated program, profits and losses will be split in the US.
|GlaxoSmithKline, Immatics Biotechnologies||Feb 2020||1150||Development, licensing and option agreement for novel adoptive cell therapies|
Immatics Biotechnologies has entered into a strategic collaboration agreement with GSK to develop novel adoptive cell therapies targeting multiple cancer indications.
The companies will collaborate on the identification, research and development of next-generation T-Cell Receptor (TCR) Therapeutics with a focus on solid tumors.
The parties will initially develop autologous T-cell therapies with the option to add allogeneic cell therapies using Immatics’ ACTallo approach.
The companies intend to utilize proprietary TCRs identified by Immatics’ XCEPTOR TCR discovery platform and directed against two proprietary targets, which were discovered and validated by Immatics’ XPRESIDENT technology.
Immatics will receive an upfront payment of €45 Million (~$50 million) for two initial programs and is eligible to receive over $550M in development, regulatory and commercial milestone payments for each product as well as additional royalty payments.
GSK obtains an option to select additional target programs to include in the collaboration.
For each additional program, Immatics is entitled to option, milestone and royalty payments.
Immatics will have primary responsibility for the development and validation of the TCR Therapeutics up to designation of a clinical candidate.
GSK will assume sole responsibility for further worldwide development, manufacturing and commercialization of the TCR Therapeutics with the possibility for Immatics to co-develop one or more TCR Therapeutics including the conduct of the first-in-human clinical trial upon GSK’s request.
|Abpro||Mar 2020||1100||Licensing agreement for two bispecific antibodies, ABP-100 and ABP-201|
Abpro announced the formation of a strategic partnership to advance two bispecific antibodies in key Asian markets including Greater China, Japan, and South Korea.
The strategic partnership was formed with Abpro Bio.
Abpro has granted an exclusive license to Abpro Bio to develop and commercialize two of Abpro’s bispecific antibody candidates: ABP-100 and ABP-201.
ABP-100 is in development for immuno-oncology with initial indications including gastric, breast and endometrial cancers.
ABP-201 is in development for ophthalmology with initial indications inclusive of Wet AMD (age-related macular degeneration) and diabetic macular edema.
The collaboration will also leverage Abpro’s proprietary DiversImmune antibody platform for generating novel molecules.
Abpro will lead global clinical development of the bi-specific candidates and work closely with Abpro Bio.
Key terms of the agreement include:
Abpro will receive from Abpro Bio up to $1.1 billion in total payments, including a $30 million upfront equity investment, and an additional $1.05 billion based on clinical milestones, post-approval payments, and royalties as ABP-100 and ABP-201 progress through the clinical development and regulatory approval processes in Greater China, Japan, and South Korea.
Abpro Corporation’s two co-founders, Ian Chan and Eugene Chan, as well as Robert S. Langer, PhD, Institute Professor at MIT, will join the Board of Abpro Bio Ltd.
|Atomwise, Bridge Biotherapeutics||Mar 2020||1080||Collaboration agreement for Pellino inhibitor pipeline using AI|
Atomwise and Bridge Biotherapeutics announced a research collaboration to launch up to 13 small molecule programs across multiple therapeutic areas using structure-based AI technology for drug discovery.
Atomwise will use its AI technology and homology modeling capabilities to evaluate Pellino E3 ubiquitin ligases and their interactions with target protein substrates.
Atomwise and Bridge will rapidly cycle through the design and testing of potent small molecule compounds, evaluating billions of possibilities that will selectively inhibit Pellino proteins.
Atomwise will receive upfront, milestone, and royalty payments upon success of each research program.
Based upon historical averages for small molecule drugs, Atomwise estimates that it could receive up to $1.08B (including royalties) with success in all research programs.
|Boehringer Ingelheim, Enleofen Bio||Jan 2020||1000||Licensing agreement for preclinical interleukin-11 (IL-11) platform|
Boehringer Ingelheim and Enleofen Bio announced the acquisition of worldwide exclusive rights to Enleofen’s preclinical interleukin-11 (IL-11) platform by Boehringer Ingelheim to develop first-in-class therapies across a broad range of fibro-inflammatory diseases.
The new partnership combines Boehringer Ingelheim’s leading expertise and comprehensive pipeline in fibrotic diseases with Enleofen’s world-leading expertise in IL-11 biology and the company’s extensive range of therapeutic antibodies targeting this pathway.
The acquisition of the IL-11 program from Enleofen strengthens Boehringer Ingelheim’s pipeline portfolio, which combines approaches that are effective across multiple fibrotic diseases with disease-specific approaches to achieve greater therapeutic effect and builds on the experience gained with nintedanib in fibrotic lung diseases.
Boehringer Ingelheim will be solely responsible for the clinical, regulatory and commercial development of the licensed therapies.
Enleofen may receive earn out payments in excess of one billion USD per product in upfront and success-based development and commercialization milestones.
|Adaptimmune, Astellas Pharma, Universal Cells||Jan 2020||897.5||Co-development and co-promotion agreement for stem-cell derived allogeneic T-cell therapies|
Astellas Pharma, through its wholly-owned subsidiary Universal Cells, and Adaptimmune Therapeutics have entered into a co-development and co-commercialization agreement to bring new stem-cell derived allogeneic T-cell therapies to people with cancer.
Astellas and Adaptimmune will agree on up to three targets and co-develop T-cell therapy candidates directed to those targets.
These targets will exclude target specific T-cell products in pre-clinical or clinical trials or those developed for other partners at Adaptimmune.
The collaboration will leverage Adaptimmune's target identification and validation capabilities for generating target-specific T-cell Receptors (TCRs), chimeric antigen receptors (CARs), and HLA-independent TCRs that recognize surface epitopes independently of the HLA profile of the tumor cell.
The collaboration will also utilize Astellas’ Universal Donor Cell and Gene Editing Platform it obtained through the acquisition of Seattle-based Universal Cells.
Astellas will fund research up until completion of a Phase 1 trial for each candidate.
Upon completion of the Phase 1 trial for each candidate, Astellas and Adaptimmune will elect whether to progress with co-development and co-commercialization of the candidate, or to allow the other Party to pursue the candidate independently through a milestone and royalty bearing licence, with the agreement allowing for either company to opt out.
The companies will each have a co-exclusive licence covering the co-development and co-commercialization of the product candidates within the field of T-cell therapy.
If a candidate is developed by one company only, the appropriate licences will become exclusive to the continuing party.
Astellas will also have the right to select two targets and develop allogeneic cell therapy candidates independently.
Astellas will have sole rights to develop and commercialize these products, subject to necessary licenses and the payment of milestones and royalties.
Adaptimmune may receive up to $897.5 million in payments, including:
An upfront payment of $50 million.
Development milestones totalling up to $73.75 million for each product if the collaboration product discovered in this partnership is co-developed and commercialized by both companies
Up to $147.5 million in milestone payments per product and up to $110 million in sales milestones for products developed unilaterally by Astellas.
Adaptimmune will receive research funding of up to $7.5 million per year.
Adaptimmune would receive tiered royalties on net sales in the mid-single to mid-teen digits.
Astellas may receive up to $552.5 million, including:
Up to $147.5 million in milestone payments per product and up to $110 million in sales milestones for products developed unilaterally by Adaptimmune.
Astellas would receive tiered royalties on net sales in the mid-single to mid-teen digits.
To the extent that Astellas and Adaptimmune co-develop and co-commercialize any T-cell therapy, they will equally share the costs of such co-development and co-commercialization, with the resulting profits from co-commercialization also shared equally.
Further details governing co-development and co-commercialization will be articulated in a product-specific commercialization agreement.
|Evox Therapeutics, Takeda Pharmaceutical||Mar 2020||882||Collaboration and option agreement for multi-target collaboration is focussed on developing up to five novel protein replacement and mRNA therapies|
Evox Therapeutics announced the signing of a rare disease-focused partnership with Takeda Pharmaceutical.
The multi-target collaboration is focussed on developing up to five novel protein replacement and mRNA therapies, including Evox's preclinical programme in Niemann-Pick disease type C (NPC) and a second new programme directed at another undisclosed rare disease.
As part of the deal, Takeda also has the option to select up to three additional rare disease targets.
The partnership with Takeda enables Evox to continue advancing its proprietary exosome-based targeting and delivery technology, while also leveraging Takeda's extensive development and clinical expertise to advance these partnered programmes into the clinic.
Evox will be eligible to receive up to $44 million in upfront, near-term milestone payments and research funding.
Evox is eligible to receive approximately $882 million in upfront, development, and commercial milestone payments from Takeda.
Evox will also receive tiered royalties on net sales of each product.
Evox will be primarily responsible for research and development activities for each programme until IND-enabling studies and for manufacturing up to and including Phase 1 clinical trials.
Takeda will reimburse Evox for manufacturing costs incurred after the pre-clinical handover of the programmes.
|Eli Lilly, Sitryx||Mar 2020||880||Collaboration and licensing agreement for immunometabolic medicines|
Eli Lilly announced an exclusive global licensing and research collaboration with Sitryx.
The collaboration will study up to four novel preclinical targets identified by Sitryx that could lead to potential new medicines for autoimmune diseases.
Sitryx will receive an upfront payment of $50 million and Lilly will make a $10 million equity investment in Sitryx.
Sitryx will be eligible to receive potential development milestones up to $820 million, as well as commercialization milestones and royalty payments on potential sales in the mid- to high-single digit range.
In return, Sitryx will grant Lilly an exclusive, worldwide license to develop and commercialize up to four novel immunometabolism targeted therapeutics, including Sitryx's two lead projects.
Lilly and Sitryx will establish a 5-year research collaboration to support the development of the therapeutics, with Sitryx responsible for drug discovery, while Lilly will fund and manage the clinical development and commercial phase of the collaboration.
|Abbvie, Alpine Immune Sciences||Jun 2020||865||Development, option and licensing agreement for ALPN-101|
Alpine Immune Sciences and AbbVie announced an exclusive worldwide option and license agreement for ALPN-101, a first-in-class dual CD28/ICOS costimulation antagonist.
Alpine will receive an upfront payment of $60 million, and will also be eligible to receive up to an aggregate of $805 million for exercise of the option and success-based development, regulatory and commercial milestones.
Alpine is eligible to receive tiered royalties on net sales of ALPN-101.
AbbVie will receive an option to an exclusive license for ALPN-101.
During the option period, Alpine will conduct a phase 2 study in systemic lupus erythematosus.
Upon exercise of the option, AbbVie will conduct all future clinical development, manufacturing and commercialization activities for ALPN-101.
|Hypera Pharma, Takeda Pharmaceutical||Mar 2020||825||Asset purchase agreement for over-the-counter and prescription pharmaceutical products|
Takeda Pharmaceutical has entered into an agreement to divest a portfolio of select non-core products exclusively in Latin America to Hypera for a total value of $825M USD.
The portfolio includes over-the-counter and prescription pharmaceutical products sold in Brazil, Mexico, Argentina, Colombia, Ecuador, Panama and Peru, which are part of Takeda’s Growth & Emerging Markets Business Unit.
The non-core products in this latest transaction generated revenues of approximately $215 million USD in Fiscal Year 2018, driven by sales of key products such as Neosaldina, Nesina, and Dramin.
Takeda has entered into an agreement to divest the rights, title, and interest to the products in a portfolio of approximately 18 select OTC and prescription pharmaceutical assets sold in Brazil, Mexico, Argentina, Colombia, Ecuador, Panama and Peru - to Hypera Pharma for a total value of $825M USD.
Takeda anticipates that approximately 300 commercial employees supporting the divested assets will be given the opportunity to transition over to Hypera Pharma at the close of this transaction.
Takeda and Hypera Pharma have also entered into a manufacturing and supply agreement under which Takeda will continue to manufacture these products and supply them to Hypera Pharma.
The transaction is expected to close in the second half of 2020, subject to the satisfaction of customary closing conditions.
Until then, Takeda remains the owner of these products and responsible for ensuring patient access to them.
|BioNTech, Pfizer||Mar 2020||748||Co-development and distribution agreement for potential COVID-19 vaccine|
BioNTech and Pfizer disclosed additional details of their collaboration to advance candidates from BioNTech’s mRNA vaccine program, previously announced on March 17, 2020.
Collaboration aims to rapidly advance multiple COVID-19 vaccine candidates into human clinical testing based on BioNTech’s proprietary mRNA vaccine platforms, with the objective of ensuring rapid worldwide access to the vaccine, if approved.
The collaboration will leverage Pfizer’s broad expertise in vaccine research and development, regulatory capabilities, and global manufacturing and distribution network.
The two companies plan to jointly conduct clinical trials for the COVID-19 vaccine candidates initially in the United States and Europe across multiple sites.
BioNTech and Pfizer intend to initiate the first clinical trials as early as the end of April 2020, assuming regulatory clearance.
During the clinical development stage, BioNTech and its partners will provide clinical supply of the vaccine from its GMP-certified mRNA manufacturing facilities in Europe.
BioNTech and Pfizer will work together to scale-up manufacturing capacity at risk to provide worldwide supply in response to the pandemic.
BioNTech and Pfizer will also work jointly to commercialize the vaccine worldwide (excluding China, which is already covered by BioNTech’s collaboration with Fosun Pharma) upon regulatory approval.
Pfizer will pay BioNTech $185 million in upfront payments, including a cash payment of $72 million and an equity investment of $113 million.
BioNTech is eligible to receive future milestone payments of up to $563 million for a potential total consideration of $748 million.
Pfizer and BioNTech will share development costs equally. Initially, Pfizer will fund 100 percent of the development costs, and BioNTech will repay Pfizer its 50 percent share of these costs during the commercialization of the vaccine.
Pfizer and BioNTech have agreed to a letter of intent regarding the co-development and distribution (excluding China) of a potential mRNA-based coronavirus vaccine aimed at preventing COVID-19 infection.
The companies have executed a Material Transfer and Collaboration Agreement to enable the parties to immediately start working together.
The collaboration aims to accelerate development of BioNTech’s potential first-in-class COVID-19 mRNA vaccine program, BNT162, which is expected to enter clinical testing by the end of April 2020.
The rapid advancement of this collaboration builds on the research and development collaboration into which Pfizer and BioNTech entered in 2018 to develop mRNA-based vaccines for prevention of influenza.
The companies expect to utilize multiple research and development sites from both companies, including in the United States and Germany, to house the activities identified by the collaboration agreement.
The companies will begin collaborating immediately.
They will finalize details of the agreement regarding financial terms, and all activities related to development, manufacturing and potential commercialization over the next few weeks.
|Selecta Biosciences, Swedish Orphan Biovitrum||Jun 2020||730||Licensing agreement for SEL-212|
Swedish Orphan Biovitrum and Selecta Biosciences have entered into a strategic licensing agreement for the product candidate SEL-212.
SEL-212 is a combination of Selecta’s tolerogenic ImmTOR immune tolerance platform and a therapeutic uricase enzyme (pegadricase) that is designed to durably control serum uric acid, reduce immunogenicity, and allow for repeated monthly dosing for the treatment of chronic refractory gout.
Sobi will assume responsibility for development, regulatory, and commercial activities for SEL-212 in all markets outside of China.
Sobi will make initial payments to Selecta of USD 100 million, which include USD 75 million up-front license fee and USD 25 million in a private placement of shares of Selecta common stock.
Selecta is eligible to receive potential milestone payments of up to USD 630 million from Sobi, which are dependent upon specific regulatory and development targets having been met, as well as sales thresholds.
Selecta is eligible to receive tiered double-digit royalties on net sales.
Sobi and Selecta have entered into a share purchase agreement, pursuant to which Sobi will invest USD 25 million in a private placement of 5,416,390 shares of Selecta common stock at a purchase price of USD 4.62 per share (representing a 20% premium to the volume weighted average price over the 10 days prior to signing).
|Biogen, Pfizer||Jan 2020||710||Licensing agreement for PF-05251749|
Biogen announced an agreement to acquire from Pfizer PF-05251749, a novel CNS-penetrant small molecule inhibitor of casein kinase 1 (CK1), for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases.
Biogen plans to develop the Phase 1 asset for the treatment of Sundowning in Alzheimer’s disease (AD) and Irregular Sleep Wake Rhythm Disorder (ISWRD) in Parkinson’s disease (PD).
The purchase will include an upfront payment of $75 million with up to $635 million in potential additional development and commercialization milestone payments, as well as tiered royalties in the high single digits to sub-teens.
|Kyowa Hakko Kirin, MEI Pharma||Apr 2020||682.5||co-development, co-promotion and licensing agreement for ME-401|
MEI Pharma and Kyowa Kirin have entered into a global license, development and commercialization agreement to further develop and commercialize MEI's ME-401, an oral, once-daily, investigational drug-candidate, selective for phosphatidylinositol 3-kinase delta (PI3Kδ), in clinical development for the treatment of B-cell malignancies.
MEI and Kyowa Kirin will co-develop and co-promote ME-401 in the U.S., with MEI booking all revenue from U.S. sales.
Kyowa Kirin has exclusive commercialization rights outside of the U.S.
Under the terms of the agreement, which substantially retains and consolidates the terms of the 2018 license agreement between MEI and Kyowa Kirin to develop and commercialize ME-401 in Japan, MEI will receive a $100 million upfront payment from Kyowa Kirin.
MEI is also eligible to receive up to $582.5 million in additional payments from Kyowa Kirin depending on the achievement of certain U.S. and ex-U.S. development, regulatory and commercial milestones.
If approved by FDA in the U.S., MEI and Kyowa Kirin will co-promote ME-401, with MEI booking all revenue from sales.
MEI and Kyowa Kirin will share U.S. profits and costs (including development costs) on a 50-50 basis.
Outside the U.S., Kyowa Kirin will have exclusive commercialization rights, lead commercialization and book all revenues from sales of ME-401.
Kyowa Kirin will pay MEI escalating tiered royalties on ex-U.S. sales starting in the teens.
Kyowa Kirin will be responsible for all incremental ex-U.S. clinical development costs and all ex-U.S. regulatory, CMC and commercial costs.
The companies have agreed to a development plan designed to broadly evaluate ME-401 in patients with various B-cell malignancies, including in combination with other agents.
|Elevar Therapeutics, Oasmia Pharmaceutical||Mar 2020||678||Licensing agreement for Apealea|
Elevar Therapeutics announced an agreement with Oasmia Pharmaceutical to obtain global rights for Apealea, except in Nordics, Russia, and certain countries in Eastern Europe.
Elevar and Oasmia have created a joint development committee for Apealea to expand approvals in Ovarian cancer worldwide while driving development in additional indications.
Although the full terms of the deal have not been disclosed, Oasmia will receive an upfront payment of $20M and up to $658M in additional regulatory and sales milestones.
|Empirico, Ionis Pharmaceuticals||Jan 2020||660||Collaboration agreement for Discovery and development of novel antisense oligonucleotide therapeutics|
Empirico has entered into a strategic collaboration with Ionis Pharmaceuticals.
During the three-year collaboration, Empirico will utilize its Precision Insights Platform, which incorporates huge biological data sets, human genetics and advanced algorithmic approaches, to identify therapeutic targets for indications and tissues that are amenable to Ionis’ industry-leading antisense technology.
Ionis can advance up to ten targets identified by Empirico and assume responsibility for all preclinical and clinical development activities.
Empirico and Ionis will also work together to incorporate human genetics evidence into ongoing efforts with existing Ionis programs, including work on target validation, indication and biomarker selection, and patient stratification.
Ionis has made a $10 million equity investment in Empirico, with additional near-term commitments of up to $30 million based on operational and preclinical milestones.
Empirico will be eligible to receive in excess of $620 million for the achievement of clinical development, regulatory and commercial milestones, and royalties on net sales.
Empirico also has the option to license, develop, and commercialize an Ionis development candidate directed toward a collaboration target for which Ionis will receive milestone payments and royalties on net sales.
|Biomedical Advanced Research and Development Authority, Emergent BioSolutions, US Government||Jun 2020||628||Contract service agreement for COVID-19 vaccine development and manufacturing|
Emergent BioSolutions has been issued a task order under an existing contract with the Biomedical Advanced Research and Development Authority to deploy its contract development and manufacturing (CDMO) capacities, capabilities, and expertise to support the U.S. government’s efforts to accelerate delivery of COVID-19 vaccines.
This task order, valued at approximately $628 million, is being issued under the company’s 2012 contract with BARDA that established Emergent’s Baltimore Bayview facility as a Center for Innovation in Advanced Development and Manufacturing (CIADM) for pandemic preparedness, and expands the partnership to include investments in Emergent’s Baltimore Camden and Rockville facilities, creating a U.S.-based manufacturing supply chain for pharmaceutical and biotechnology innovators of COVID-19 vaccine candidates.
Under the task order, Emergent will deploy its molecule-to-market CDMO offering, committing manufacturing capacity, valued at approximately $542.7 million, for production of COVID-19 vaccine candidates through 2021.
This award secures, on behalf of leading COVID-19 vaccine innovators that are supported by the U.S. government, capacity for drug substance manufacturing at the company’s Baltimore Bayview facility and for drug product manufacturing at the Baltimore Camden and Rockville locations.
The task order also includes an investment of approximately $85.5 million for the rapid expansion of Emergent’s viral and non-viral CDMO drug product fill/finish capacity at the Baltimore Camden and Rockville facilities.
|Esperion Therapeutics, Otsuka||Apr 2020||610||Development and licensing agreement for NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) Tablets|
Esperion have entered into a collaboration agreement with Otsuka Pharmaceutical for the development and commercialization of NEXLETOL and NEXLIZET tablets in Japan.
Both medicines were recently approved in both the US and EU.
The collaboration advances the commitment of both companies to provide cost-effective, oral, once-daily, non-statin LDL-cholesterol (LDL-C) lowering medicines for hypercholesterolemia patients in Japan.
This development and commercialization collaboration combines Esperion’s expertise in lipid management with Otsuka’s deep cardiovascular drug development and commercialization expertise in Japan.
Esperion will grant Otsuka exclusive rights to NEXLETOL and NEXLIZET tablet development and commercialization in Japan.
Otsuka will be responsible for all development, regulatory, and commercialization activities in Japan.
Otsuka will fund all Japan-specific development costs associated with the program.
Esperion estimates this amount to total up to $100 million over the next few years.
Esperion will receive an upfront cash payment of $60 million as well as up to an additional $450 million in total development and sales milestones.
Esperion will also receive tiered royalties from 15 percent to 30 percent on net sales in Japan.
|Gilead Sciences, Kite Pharma, Kyverna Therapeutics||Jan 2020||587.5||Collaboration and licensing agreement for engineered T cell therapies|
Kyverna has entered into a strategic collaboration and license agreement with Gilead to develop engineered T cell therapies for the treatment of autoimmune disease based on Kyverna's synthetic Treg platform and synNotch technology from Kite.
Kyverna will be responsible for conducting research activities and initial clinical studies through proof-of-concept and Gilead will be granted an option, upon the exercise of which Gilead will be solely responsible for further clinical development and commercialization efforts for these programs.
Gilead will make to Kyverna an upfront payment of $17.5 million and Kyverna may earn an additional $570 million in development and commercialization milestones.
Kyverna will also continue to advance its platform and develop proprietary programs beyond the Gilead collaboration.
|LEO Pharma, Microbio Shanghai, Oneness Biotech||Apr 2020||570||Licensing agreement for FB825|
LEO Pharma has signed a worldwide exclusive licensing agreement with Oneness Biotech and Microbio Shanghai covering the development and commercialization of the novel Atopic Dermatitis (AD) and Allergic Asthma drug candidate, FB825.
LEO Pharma will make an upfront payment of USD 40 million and offer milestone payments up to USD 530 million, followed by a tiered high single-digit to double-digit royalties.
Oneness will be responsible for executing the Phase 2a study for Atopic Dermatitis in the United States and Microbio Shanghai will execute the Phase 2a study for allergic asthma in China.
LEO Pharma will assume all the development responsibilities after the Phase 2a studies.
|Supernus Pharmaceuticals, US WorldMeds||Apr 2020||530||Asset purchase agreement for CNS portfolio|
Supernus Pharmaceuticals has entered into a definitive agreement under which Supernus will acquire the CNS portfolio of US WorldMeds.
With the acquisition, Supernus adds three established and marketed products in the U.S. market with a product candidate in late-stage development:
APOKYN (apomorphine hydrochloride) injection is used, as needed, to provide rapid, reliable, and robust control of body movements in people with Parkinson’s disease (PD) when they experience an off episode. An off episode, also called hypomobility, may include symptoms such as muscle stiffness, slow movements, and difficulty starting movements.
MYOBLOC® (rimabotulinumtoxinB) injection is the first and only approved botulinum toxin Type B injectable indicated for the treatment of cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia in adults, and the treatment of chronic sialorrhea in adults.
XADAGO® (safinamide) tablets is a monoamine oxidase type B (MAO-B) inhibitor indicated as a daily adjunctive treatment to levodopa/carbidopa in patients with PD experiencing off episodes.
Apomorphine Infusion Pump is a product candidate for the continuous treatment of motor fluctuations (“on‐off” episodes) in PD patients whose motor control is unsatisfactory with oral levodopa and at least one other noninvasive PD therapy. New Drug Application (NDA) submission is expected in the second half of 2020 with potential launch, if approved by the FDA, in the second half of 2021.
Total consideration of $530 million consists of an upfront cash payment of $300 million plus regulatory and commercial milestone cash payments up to $230 million.
All cash consideration will be funded through existing balance sheet cash.
|Navitor Pharmaceuticals, Supernus Pharmaceuticals||Apr 2020||525||Co-development and option agreement for mTORC1 Activator NV-5138|
Supernus Pharmaceuticals and Navitor Pharmaceuticals announced a joint development and option agreement for Navitor’s mTORC1 activator, NV-5138.
Supernus and Navitor will jointly conduct a Phase II clinical program for NV-5138 in TRD.
Supernus will pay the costs of Phase II development up to $50 million, plus certain costs associated with nonclinical development and formulation.
In addition, Navitor has granted Supernus an exclusive option to license or acquire NV-5138 in all world territories, excluding Greater China, prior to initiation of a Phase III clinical program.
In exchange for the option to license or acquire NV-5138, Navitor will receive an upfront payment of $25 million, composed of a $10 million option fee and a $15 million equity investment representing approximately 13% ownership in Navitor.
Total payments, exclusive of royalty payments on net sales of NV-5138 and development costs under the agreement, have the potential to reach $410 million to $475 million, which includes the upfront payment of $25 million, an additional license or acquisition fee depending on whether Supernus ultimately licenses or acquires NV-5138, and subsequent clinical, regulatory and sales milestone payments.
Supernus also will have the first right of refusal for any compound with a similar mechanism of action on mTORC1 as NV-5138 in the central nervous system.
In conjunction with the equity investment, Jack Khattar, President and CEO of Supernus, will join the Board of Directors of Navitor.
|ACADIA Pharmaceuticals, Vanderbilt University||May 2020||525||Research and licensing agreement for drug candidates targeting the muscarinic M1 receptor for range of central nervous system|
ACADIA Pharmaceuticals and Vanderbilt University announced an exclusive worldwide license agreement to develop and commercialize novel drug candidates targeting the muscarinic M1 receptor with the potential to treat a range of central nervous system (CNS) disorders.
The collaboration will focus on positive allosteric modulators (PAMs) of the M1 receptor.
The WCNDD has been developing highly selective PAMs of the M1 subtype of muscarinic acetylcholine receptor, which may represent a novel approach for improving cognitive function and other neuropsychiatric symptoms in patients suffering from CNS disorders.
The agreement includes a lead compound currently in Phase 1 testing, as well as compounds currently in preclinical development and compounds generated in an ongoing discovery program.
Vanderbilt University will receive $10 million upfront and is eligible for potential milestone payments of up to $515 million and tiered royalties.
|Pfizer, eFFECTOR Therapeutics||Jan 2020||507||Collaboration, licensing, option and co-promotion agreement for small-molecule inhibitors of eukaryotic initiation factor 4E (eIF4E)|
eFFECTOR Therapeutics and Pfizer announced an exclusive worldwide license and collaboration agreement to develop small-molecule inhibitors of eukaryotic initiation factor 4E (eIF4E), a key oncogenic driver located downstream from both the RAS and PI3K signaling pathways.
eIF4E is an effector protein that is activated in a variety of human cancers and is linked to poor prognosis and resistance to certain therapies.
eFFECTOR will receive a $15 million payment upfront, and will be eligible for additional potential $492M in R&D funding, development and sales milestone payments.
eFFECTOR will receive royalties on sales of any products that may result from this collaboration if the program reaches commercialization and has an option to enter into a co-promotion and profit and loss share arrangement in the United States.